Mr. James Durward reports

NDATALYZE CORP. ("NDAT" OR THE "CORPORATION") (CSE:NDAT) (OTC:NDATF) ANNOUNCES A BINDING CLINICAL STUDY AGREEMENT.

On Dec. 5, 2023, Ndatalyze Corp. signed a binding clinical study agreement with Personalized Prescribing Inc., pursuant to a previously announced letter of intent (LOI) with the same company. The corporation is now making changes to its biometric questionnaire to simplify the clinical study data collection process, which changes are expected to be complete before Dec. 10, 2023, thus allowing the data collection to begin before year-end. Because the DNA data already exist, the contemplated data collection is expected to happen in a short period of time after which the unique data set is expected to be forwarded to Dr. Dale Stevens of York University's faculty of health, department of psychology, where correlation, integration and validation work is to be done pursuant to a previously announced Mitacs project. The arrangement of the Mitacs project is continuing.

About Ndatalyze Corp.

Ndatalyze uses evidence-based, objective data from whole life experiences to predict individual mental states over time and applies this knowledge toward a fuller understanding of how mental health develops and to improve mental well-being. The company combines machine learning with a proprietary reference database that contains greater than 1,200 persons' genetic expressions, childhood environment, habits, phobias, lived experiences and lifestyle to generate a personalized graphic report predicting an individual's predisposition toward a variety of common mental conditions, both current and forward in time.

We seek Safe Harbor.